Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short-Term Debt issuances (2016 - 2017)

IGC Pharma (IGC) has disclosed Short-Term Debt issuances for 8 consecutive years, with $76911.0 as the latest value for Q4 2017.

  • On a quarterly basis, Short-Term Debt issuances rose 377.04% to $76911.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$448428.0, a 15.77% increase, with the full-year FY2017 number at -$476190.0, up 61.98% from a year prior.
  • Short-Term Debt issuances was $76911.0 for Q4 2017 at IGC Pharma, up from -$76911.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $414321.0 in Q1 2015 to a low of -$766903.0 in Q3 2015.
  • A 5-year average of -$75444.4 and a median of -$2797.0 in 2014 define the central range for Short-Term Debt issuances.
  • Peak YoY movement for Short-Term Debt issuances: crashed 25244.36% in 2015, then surged 377.04% in 2017.
  • IGC Pharma's Short-Term Debt issuances stood at $101999.0 in 2013, then tumbled by 143.45% to -$44322.0 in 2014, then soared by 148.39% to $21447.0 in 2015, then crashed by 229.44% to -$27762.0 in 2016, then soared by 377.04% to $76911.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Short-Term Debt issuances are $76911.0 (Q4 2017), -$76911.0 (Q3 2017), and -$448428.0 (Q1 2017).